Press ReleasesCordenPharma Signs Multi-Year Agreement for the Manufacturing of a Commercial Peptide

10 January 2023 -- Luxembourg -- CordenPharma is pleased to announce the signing of a multi-year agreement commencing in 2023 for the contract manufacturing of a large-volume peptide at its CordenPharma Colorado facility.

The manufacturing agreement will potentially cover a value of ca. USD 1 billion, depending on actual production over the term of the agreement, and will support the launch of an innovative peptide. The companies have agreed not to disclose additional details and respect customer confidentiality.

Dr Michael Quirmbach, CEO & President of CordenPharma, commented: “We are very excited about the trust our customer has placed in CordenPharma, and are pleased to continue supporting the commercial manufacturing of this innovative peptide at our CordenPharma Colorado (US) site, which is perfectly equipped for producing these types of complex molecules.

As part of our commitment, we plan to further expand both our large and medium-scale peptide manufacturing capacity at our Colorado and Frankfurt sites, making CordenPharma the leading peptide manufacturing CDMO with full drug product integration, possible via our aseptic fill and finish capabilities in CordenPharma Caponago.”

In parallel, CordenPharma is pursuing a large investment program across its global facility network to expand capacities and technologies in key areas such as Peptides, Lipids, and Injectables, with an overall planned investment of > €200M in 2023.

About CordenPharma
CordenPharma is a full-service partner in the Contract Development & Manufacturing (CDMO) of innovative APIs, Lipid Excipients, and Drug Products. Through a growing network of cGMP facilities across Europe and the US organized under five Technology Platforms - Peptides - Lipids & Carbohydrates - Injectables - Highly Potent & Oncology - Small Molecules - CordenPharma experts translate complex processes and projects at any stage of development into high-value products. For more information about CordenPharma, contact us or visit


Human-Centred Design: From Inception to Integration

IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process


The Importance of Temperature Control in Pharmaceutical Analysis

As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research


Providing Support Throughout the Patient Journey

Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?